Extended-acting Houses and likely connected risks with SUNLENCA: Residual concentrations of SUNLENCA may perhaps continue to be within the systemic circulation of people for approximately 12 months or extended. SUNLENCA may raise exposure, and potential possibility of adverse reactions, to drugs generally metabolized by CYP3A initiated within nine